Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. The Life Sciences and Diagnostics Markets segment offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. The Applied Markets segment refers to the application-focused solutions that include instruments and software that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products. The Agilent CrossLab segment spans the entire lab with its extensive services and consumables portfolio in addition to software and laboratory automation solutions. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Jul-09-26 | Resumed | Jefferies | Hold | $135 |
| Jun-26-26 | Resumed | Bernstein | Outperform | $155 |
| Jun-11-26 | Initiated | Piper Sandler | Neutral | $150 |
| May-28-26 | Upgrade | BofA Securities | Neutral → Buy | $145 |
| May-27-26 | Initiated | RBC Capital Mkts | Outperform | $153 |
| Jan-20-26 | Initiated | HSBC Securities | Buy | $180 |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform | $160 |
| Dec-15-25 | Upgrade | Barclays | Equal Weight → Overweight | $165 |
| Dec-09-25 | Initiated | Goldman | Buy | $170 |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight | $270 |
| Oct-08-25 | Upgrade | UBS | Neutral → Buy | $170 |
| Oct-08-25 | Initiated | Rothschild & Co Redburn | Buy | $165 |
| Feb-10-25 | Upgrade | Barclays | Underweight → Equal Weight | $135 → $145 |
| Aug-28-24 | Initiated | Wells Fargo | Overweight | $157 |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy | $135 → $150 |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform | |
| Jun-03-24 | Resumed | Jefferies | Hold | $135 |
| Apr-05-24 | Upgrade | Stifel | Hold → Buy | $145 → $163 |
| Dec-13-23 | Initiated | Wolfe Research | Outperform | $140 |
| Dec-12-23 | Downgrade | BofA Securities | Buy → Neutral | $130 → $133 |